News Article | May 17, 2017
The global Carcinoid Syndrome Management market has been evaluated as average growing market and expected that the market will reach high growth figures in coming years. The global market for carcinoid syndrome management is highly consolidated and very rare number of players constitutes the entire market. Chemotherapy treatment type segment is expected to dominate the global market for carcinoid syndrome management over the forecast period as chemotherapy is used as a first line treatment. Newly introduced hepatic artery embolization agents are anticipated to gain the significant share in the global market over the forecasted period. The market is expected to grow at an average CAGR due to growing awareness towards the symptoms of carcinoid tumor among the general population. The primary factor driving the growth of global carcinoid syndrome market is incidence of carcinoid tumor. As per National Institute of Health statistics, worldwide rate of carcinoid tumor is 2 per 100,000 person with high incidence of GI carcinoid tumors. Every year over 8,000 patients in the U.S are identified with carcinoid tumor in GI tract. Other factors influencing the global carcinoid syndrome management market include increasing incidence of hormonal disorders, growing smoking habits, levels of carcinogen in highly developed countries etc. Factor restraining the growth of global carcinoid syndrome management market is no availability of drugs approved to manage carcinoid syndrome. • Novartis International AG (Sandoz) (Switzerland), • Pharmascience Inc. (Canada), • Omega Laboratories Ltd. (Canada), • Teva Pharmaceutical Industries Ltd. (Israel), • Mylan N.V. (USA), • Ipsen Biopharmaceuticals, Inc.(US), • Sirtex Medical Limited (Australia) , • BTG International Ltd. (UK), • Wockhardt Ltd. , • Sun Pharmaceutical Industries Limited (India), Commenting on the report, an analyst from Market Research Future (MRFR)’s team said: the market for carcinoid syndrome management is growing due to growing incidence of carcinoid tumor, increasing incidence of hormonal disorders, growing smoking habits, levels of carcinogen in highly developed countries etc. The only factor restraining the growth of global carcinoid syndrome management market is no convenience of drugs approved to manage carcinoid syndrome. There are various factors and opportunities which help the global Carcinoid Syndrome Management market to grow, the major driving factors includes innovations and advancements in in medicine and drug discovery system, also the rising disposable income of the people in developing countries enabling them to afford high price treatment. Some of the factors which hamper the growth of carcinoid syndrome management market includes high cost of treatment which includes chemotherapy and others. The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. Test the market data and market information presented through more than 50 market data tables and figures spread over 80 numbers of pages of the project report. Avail the in-depth table of content TOC & market synopsis on “Carcinoid Syndrome Management market Research Report –Global Forecast to 2022” Asia Pacific is expected to be the fastest growing market and is expected to continue to grow at the same rate during the forecasted period. North America with the largest market share of 70% in 2013 of the global Carcinoid Syndrome Management market due to high prevalence of diseases, and easy availability of Carcinoid Syndrome Management treatment facilities due to widespread healthcare infrastructure and government encouragement to medical innovation and is expected to grow further during the forecasted period. Developing countries were reported to have maximum cases of the disease but due to lack of technology advancement and healthcare facilities and also because of high cost of treatment and check-up and lack of awareness, only few cases were reported and treated in the last 7 years. The global carcinoid syndrome management market is segmented on the basis of organs affected by the disease, treatment procedures and end users. Based on organs affected by the disease, the market has been segmented into small intestine, lungs, rectum, appendix, colon, stomach, pancreas, liver and others. Small intestine are the most likely to get affected by the disease and maximum cases reported were of the small intestine only. Other organs constitute rare chances of getting affected. Based on treatment type, the market has been segmented into chemotherapy, biological therapy, and hepatic artery embolization agents. Further on the basis of end users the market has been segmented as hospital, clinics, and cancer institute and treatment centers. Browse Related Report Middle East and Africa Critical Care Equipment (CCE) Market information, by Type (Patient Monitor, Medical Ventilator, Dialysis, IV Pumps, Infusion pump, Suction Apparatus, and others), by End users (Hospitals, Research laboratories and others) - Forecast to 2023 https://www.marketresearchfuture.com/reports/mea-critical-care-equipment-market-2751 About Market Research Future: At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions. For more information, please visit https://www.marketresearchfuture.com/reports/carcinoid-syndrome-management-market-2843
Rocheleau M.-J.,Omega Laboratories Ltd. |
Rocheleau M.-J.,PARC Inc. |
Larouche E.,Omega Laboratories Ltd. |
Salamu C.,Omega Laboratories Ltd. |
Curca M.,Omega Laboratories Ltd.
Journal of Pharmaceutical Analysis | Year: 2012
Liquid chromatography (LC) is considered by many as a mature technique. Nonetheless, LC technology continues to evolve driven by the need for high-throughput and high-resolution analyses. Over the past several years, small particle size packing materials have been introduced by several column manufacturers to enable fast and efficient LC separations. Several examples of pharmaceutical analyses, including impurity profiling of taxanes and atracurium besylate, in-process testing of peptides in injectable dosage form, using sub-2 μm column technology are presented in this paper, demonstrating some of the capabilities and limitations of the technology. © 2012 Xian Jiaotong University.
Wyman J.F.,Cuyahoga County Regional Forensic Science Laboratory |
Lavins E.S.,Cuyahoga County Regional Forensic Science Laboratory |
Engelhart D.,Omega Laboratories Inc |
Armstrong E.J.,Cuyahoga County Regional Forensic Science Laboratory |
And 5 more authors.
Journal of Analytical Toxicology | Year: 2013
3,4-Methylenedioxypyrovalerone (MDPV) is a psychoactive, synthetic analog of the central nervous system stimulant cathinone. Its recent popularity as a recreational drug in the United States has led to numerous reports to poison control centers across the country. As with other synthetic cathinones, the recreational use of MDPV has resulted in death. MDPV is thought to exert its pharmacologic effects by inhibiting the reuptake of dopamine and norepinephrine. This report describes the case of an exposure of a 39-year-old male to MDPV, which resulted in his death. Postmortem concentrations of MDPV in various tissues were measured. The detection of MDPV in tissues and fluids was accomplished using gas chromatographymass spectrometry analysis after solid-phase extraction. Blood analysis also demonstrated therapeutic levels of lamotrigine, fluoxetine, risperidone, benztropine, pseudoephedrine and ibuprofen. The detection of cathinones in hair was conducted using high-performance liquid chromatographytandem mass spectrometry after solid-phase extraction. MDPV was uniformly distributed among multiple tissues (blood, brain, muscle, cerebrospinal fluid and lung) at concentrations of approximately 0.4 to 0.6 μg/mL. Tissue and fluids responsible for detoxification/excretion had higher concentrations of MDPV (kidney, liver and bile >0.8 μg/mL). A blood concentration >0.4 μg/mL was judged sufficient to cause death. The cause of death was ruled MDPV intoxication resulting in cardiac arrhythmia.